Terns Pharmaceuticals Inc Stock
Terns Pharmaceuticals Inc Stock price
Key metrics
| Market capitalization | $271.62m |
| Enterprise Value | $-62.64m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 0.87 |
| P/B ratio (TTM) P/B ratio | 0.83 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-103.85m |
| Free Cash Flow (TTM) Free Cash Flow | $-71.67m |
| Cash position | $334.26m |
Is Terns Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
Terns Pharmaceuticals Inc Stock Analysis
Analyst Opinions
9 Analysts have issued a Terns Pharmaceuticals Inc forecast:
Analyst Opinions
9 Analysts have issued a Terns Pharmaceuticals Inc forecast:
Financial data from Terns Pharmaceuticals Inc
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -103 -103 |
1%
1%
|
EBIT (Operating Income) EBIT | -104 -104 |
0%
0%
|
| Net Profit | -90 -90 |
1%
1%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Terns Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Terns Pharmaceuticals Inc Stock News
Company Profile
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
| Head office | United States |
| CEO | Amy Burroughs |
| Employees | 66 |
| Founded | 2017 |
| Website | ternspharma.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
